+

WO1994027624A1 - Formulations de prevention du cancer contenant des vitamines et des mineraux - Google Patents

Formulations de prevention du cancer contenant des vitamines et des mineraux Download PDF

Info

Publication number
WO1994027624A1
WO1994027624A1 PCT/CN1994/000036 CN9400036W WO9427624A1 WO 1994027624 A1 WO1994027624 A1 WO 1994027624A1 CN 9400036 W CN9400036 W CN 9400036W WO 9427624 A1 WO9427624 A1 WO 9427624A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compound
vitamin
carotene
death
Prior art date
Application number
PCT/CN1994/000036
Other languages
English (en)
Chinese (zh)
Inventor
Junyao Li
Original Assignee
Junyao Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Junyao Li filed Critical Junyao Li
Publication of WO1994027624A1 publication Critical patent/WO1994027624A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof

Definitions

  • the invention relates to a medicine compound, in particular a vitamin / mineral medicine compound, for preventing the occurrence of human cancer.
  • cancer is a common and frequently-occurring disease that seriously endangers human health and life. It has become the leading cause of death for residents in many countries or regions. According to WHO estimates, at least 6 million people worldwide are killed by cancer every year, and 9 countries or regions have cancer, and cancer has become the number one cause of death in the population. According to statistics published by China in 1978 on the number of deaths in some provinces, cities, and autonomous regions, cancer has become the number one cause of death for urban residents and the third cause of death for rural residents, accounting for 21 of the total deaths. 61% and 14.19%. Therefore, as early as possible, the medical difficulty of this cancer has become the urgent demand and common aspiration of human beings.
  • cancer Because the cause of human cancer and its carcinogenic mechanism have not yet been elucidated, and there is no reliable early detection method and cure method, therefore, compared with other common diseases, cancer has the highest mortality rate and the greatest threat.
  • Vitamin A compounds and their precursors carotene include: Vitamin A compounds and their precursors carotene, vitamin B compounds (riboflavin, nicotinic acid, pyrrolyl alcohol, cobalt amine, folic acid), vitamin C, vitamin E, fiber And several minerals: : xi, zinc, calcium, molybdenum, etc.
  • vitamin A compounds can also inhibit in vitro and animal experiments with lung cancer, The occurrence of esophageal cancer, gastric cancer, intestinal cancer, bladder cancer, prostate cancer, breast cancer, cervical cancer, laryngeal cancer and skin cancer, suggesting that these compounds are very promising as preventive drugs for human cancer; ⁇ Recent analytical epidemic diseases Scientific investigations can confirm that vitamin A in food or serum has a protective effect on the occurrence of esophageal or gastric cancer, and it is believed that its anti-cancer effect is more closely related to vitamin A precursor carotene.
  • vitamin A derivative I sotretionoin has been shown in clinical trials to reduce the incidence of the second primary cancer in the head and neck of oral cancer patients, and the use of vitamin A or vitamin A alone is clinical
  • the trial is currently being widely carried out among asbestos workers, tin miners, smokers, and people at high risk of skin cancer and cervical cancer, but so far no conclusion has been drawn that vitamin A can prevent cancer.
  • B vitamins are a large family, which include vitamins (lucamine), B (riboflavin), PP (nicotinic acid), B 6 (pyridine), 2 (aerocobalamin), folic acid, and pantothenic acid.
  • One of the common characteristics of regions with high incidence of esophageal cancer in the world is that residents have less B vitamins from food, especially riboflavin and niacin are more prominent; compared with the United States
  • the intake of riboflavin by the residents of Lin County is seriously insufficient (over 90% of the population is inadequate), and insufficient riboflavin can cause esophageal cell proliferation in baboons and change the metabolism of nitrosamines; on the contrary, large amounts of corn fed Rats supplemented with riboflavin, niacin, zinc, thallium, and molybdenum can inhibit the carcinogenesis of the esophagus.
  • the object of the present invention is to provide a vitamin / mineral anti-cancer compound that can reduce the incidence and mortality of cancer in human residents without significant toxic effects, and the compound can be used for the production of anti-cancer drugs. And anti-cancer food, drink and Condiments.
  • the present invention provides a vitamin / mineral compound having a preventive effect on human total death, total cancer death, gastric cancer death and onset, and the first compound is composed of the following components:
  • 3-Carotene at least 6 mg selenium yeast 5 0 ⁇ 2 0 0
  • the rest are drug carriers
  • each tablet or capsule contains at least 6 mg of 3-carotene, 50 ⁇ 2 0 0 U g of 5 yeast, 3 0 ⁇ : LOO mg of alpha-tocopherol. This can be taken only once a day for preventive purposes.
  • the above compound formula contains 15 mg of ⁇ -carotene, 50 ⁇ g of selenium yeast, 30 mg of 0; -tocopherol, and the rest as drug carriers in each tablet or capsule.
  • the second compound involved in the present invention is:
  • Riboflavin is 1.6 to 5 g
  • nicotinamide is 20 to 80 mg
  • the rest are drug carriers.
  • the second compound is also preferably made into oral dosage forms such as tablets or capsules.
  • Each tablet or capsule contains 1.6 to 5 mg of riboflavin, 20 to 80 mg of nicotinamide, and the rest are drug carriers.
  • the present invention also relates to a food incorporating the first compound or the second compound according to the present invention.
  • the food includes various instant noodles, biscuits, pastries, beverages, condiments such as soy sauce, and the like.
  • the method for preparing the vitamin / mineral compound of the present invention is well known to those skilled in the art.
  • the raw materials and auxiliary materials such as additives, excipients, stabilizers, etc. are processed and mixed in advance, or the wave-shaped raw materials are spray-dispersed to form many small droplets, and then dried instantly to obtain powder products, and then microcapsules are used.
  • the manufacturing technology uses drug powder as the capsule core and covers the surface with the original matrix of the matrix to make self-separated or independent microcapsules to ensure the isolation of substances that easily react with each other, so that the active ingredients in the formula are in a stable form. Combine into a compound.
  • the first compound has an anti-gasification effect.
  • the three components in the compound, 3-carotene, ⁇ -tocopherol, and selenium yeast, are free radical scavengers and capture agents, which can eliminate the effect of peroxide on cells. Damage caused by genetic material, protecting large molecules DN A.
  • the structure and energy of RNA and protein can reduce the carcinogenic effect of carcinogens.
  • the compound also has an anti-mutagenic effect and improves the ability of cell genetic material damage repair.
  • the compound has the ability to block the internal synthesis of nitrosamines and increase the activity of detoxifying enzymes, change the metabolic process of carcinogens in the body, and promote the inactivation of carcinogens.
  • the compound also has functions of enhancing cellular immunity and humoral immunity, inhibiting cell proliferation, and enhancing cell differentiation ability.
  • riboflavin participates in a series of physiological and biochemical metabolism in the body, which are closely related to the normal growth and energy metabolism of the tissue. Its anti-cancer effect with nicotinamide is used as a metabolic coenzyme to participate in the metabolism of carcinogens. Detoxification; enhance the body's cellular immunity and body wave immunity; also have anti-qi effect. Overview of the drawings
  • Attachment 1 Preventive effect of the first compound on total cancer death in the population
  • Example 2 Take 600 mg of ⁇ -carotene, 500 micrograms of selenium yeast, and 3 0 g of tocopherol, and add them to excipients (such as corn starch). Selenium yeast and ⁇ -tocopherol are made into microcapsules, and these three microcapsules are thoroughly mixed with a matrix such as methylcellulose, coated, and made into tablets of 250 grams in size. Combined with 6 mg beta-carotene, 50 yeast, and 30 mg alpha-fertility.
  • excipients such as corn starch
  • Example 1 150 g of ⁇ -carotene, 200 g of selenium yeast, and 0 mg of ⁇ -tocopherol 100 mg were prepared into ovalbumin for the method described in Example 1.
  • the microcapsules are coated, and then the capsules are mixed with a lactose matrix.
  • the capsules are made into oral capsules for clinical use according to methods known in the art.
  • Each capsule contains
  • ⁇ -carotene, selenium yeast and ⁇ -tocopherol can be added to the soy sauce according to a method known in the art, so that 60 mg of ⁇ -carotene is combined in each 100 ml of soy sauce, 50 0 Selenium yeast, 300 mga—tocopherol.
  • Example 4
  • Riboflavin and nicotinamide can be added to biscuits or instant noodles according to methods known in the field of food processing. Biscuits or instant noodles can be made through well-known processing techniques. The final 100 grams of product contains 5 mg of riboflavin. 8 0 g of nicotinamide. Example 5
  • each capsule contains 5 mg riboflavin and 80 mg nicotinamide.
  • the first or second compound according to the present invention is added to two beverages, such as grapefruit and orange juice, respectively, so that the concentration of the above compound in the final drink is controlled at 500 ml of each component in the drink.
  • the effective daily dose is the same.
  • the embodiments used in the present invention are not intended to limit the present invention, but merely to explain and understand the present invention. Those skilled in the art can make certain modifications based on this, but all belong to the scope of the present invention.
  • Experimental example In order to verify whether supplementation of vitamins and minerals can reduce the incidence and death of human cancer, and provide scientific basis and effective ways for the prevention and control of human cancer, the inventors conducted random, double-blind, and comfort in Linxian, Henan province, China.
  • Agent-controlled population intervention test in which the general population test, 29, 548 adults, using a fractional factorial design, was randomly divided into 8 groups, supplemented with four compound vitamin and mineral pills or comfort Agent for five years and three months. Regular monthly check-ups and seasonal random blood draws for biochemical measurements indicate that the subjects have a very high drug cooperation rate; the diagnosis of the incidence and death of cancer at the test endpoint and other common diseases is provided by the local medical department, supplemented by a special endoscopy Microscopy and cytology, and finally confirmed by the tertiary diagnosis group.
  • This experiment is the first successful experiment to prevent cancer with human oral multivitamins and minerals.
  • the above general population test shows that taking the first compound of the present invention, that is, supplementing the ⁇ -carotene, selenium yeast, and tocopherol groups, can significantly reduce the total mortality rate by 9%
  • the second compound of the present invention can reduce the incidence of esophageal cancer by 15% (P ⁇ 0.05) (see Tables 1, 2 and 3).
  • the second compound described in the present invention can significantly reduce the incidence of esophageal cancer (15%, P ⁇ 0.05), and can also greatly reduce the prevalence of ocular nuclear cataract in the elderly 41%. (P ⁇ 0. 0 0 1) (see Table 4).
  • Table 4 The general population test in Linxian County for the age of 55-74 years old * Rogerstic regression regression analysis of nucleus lens opacity and snoring rate Rogerstic regression analysis of crystal opacity rate 95% confidence interval supplement Not supplement
  • A-vitamin, zinc; riboflavin, nicotinic acid; C vitamin C, molybdenum;

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des formulations de prévention du cancer contenant des vitamines et des minéraux. La première formulation contient du β-carotène, du senlémium et de la vitamine A, la deuxième contient de la vitamine B2 et de l'acide nicotinique. L'invention porte également sur des aliments, des boissons et des assaisonnements contenant les formulations sus-mentionnées.
PCT/CN1994/000036 1993-05-22 1994-05-09 Formulations de prevention du cancer contenant des vitamines et des mineraux WO1994027624A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN93106009.5 1993-05-22
CN 93106009 CN1080855A (zh) 1993-05-22 1993-05-22 维生素矿物质防癌复方

Publications (1)

Publication Number Publication Date
WO1994027624A1 true WO1994027624A1 (fr) 1994-12-08

Family

ID=4986030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN1994/000036 WO1994027624A1 (fr) 1993-05-22 1994-05-09 Formulations de prevention du cancer contenant des vitamines et des mineraux

Country Status (2)

Country Link
CN (1) CN1080855A (fr)
WO (1) WO1994027624A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999048506A3 (fr) * 1998-03-23 1999-12-09 Roche Consumer Health Worldwid Composition pour application pharmaceutique et/ou complement nutritionnel chez l'homme ou l'animal
WO2000069426A3 (fr) * 1999-05-17 2001-04-12 Giampiero Valletta Utilisation d'une combinaison de vitamines pour traiter le prurit et les maladies non infectieuses se manifestant par des demangeaisons et/ou des inflammations
EP0893949A4 (fr) * 1996-01-16 2002-01-02 Univ Technology Corp Utilisation d'agents antioxydants pour le traitement de la maladie cholestatique du foie

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1082101C (zh) * 1999-04-09 2002-04-03 党建平 铝电解槽阳极下料排气缝制作工艺
CN101427723B (zh) * 2008-12-02 2011-05-18 江南大学 一种有机硒和维生素复配生产富硒功能性软糖的方法
CN108653322A (zh) * 2018-07-02 2018-10-16 福州脉趣恒生科技有限公司 一种具有预防肿瘤转移的功能性保健品的组合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948417A (ja) * 1982-09-10 1984-03-19 ロドルフオ・ワイ・アルマンゾ− 癌の処置方法
FR2609893A1 (fr) * 1987-01-26 1988-07-29 Rougereau Andre Composition a base d'acides amines et de vitamines utilisable en therapeutique cancerologique
WO1991002535A1 (fr) * 1989-08-11 1991-03-07 Basil, Inc. Composition et procede de prevention du cancer
WO1991011117A2 (fr) * 1990-02-05 1991-08-08 Board Of Regents, The University Of Texas System Complements alimentaires comprenant des vitamines et des sels mineraux
CA2057463A1 (fr) * 1991-12-11 1993-06-12 David Rowland Composition vitaminique/minerale

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5948417A (ja) * 1982-09-10 1984-03-19 ロドルフオ・ワイ・アルマンゾ− 癌の処置方法
FR2609893A1 (fr) * 1987-01-26 1988-07-29 Rougereau Andre Composition a base d'acides amines et de vitamines utilisable en therapeutique cancerologique
WO1991002535A1 (fr) * 1989-08-11 1991-03-07 Basil, Inc. Composition et procede de prevention du cancer
WO1991011117A2 (fr) * 1990-02-05 1991-08-08 Board Of Regents, The University Of Texas System Complements alimentaires comprenant des vitamines et des sels mineraux
CA2057463A1 (fr) * 1991-12-11 1993-06-12 David Rowland Composition vitaminique/minerale

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893949A4 (fr) * 1996-01-16 2002-01-02 Univ Technology Corp Utilisation d'agents antioxydants pour le traitement de la maladie cholestatique du foie
WO1999048506A3 (fr) * 1998-03-23 1999-12-09 Roche Consumer Health Worldwid Composition pour application pharmaceutique et/ou complement nutritionnel chez l'homme ou l'animal
WO2000069426A3 (fr) * 1999-05-17 2001-04-12 Giampiero Valletta Utilisation d'une combinaison de vitamines pour traiter le prurit et les maladies non infectieuses se manifestant par des demangeaisons et/ou des inflammations
JP2002544225A (ja) * 1999-05-17 2002-12-24 ジアムピエロ バレッタ そう痒症及びかゆみ及び／又は炎症を伴う非感染性疾病の治療のためのビタミンの組合せの使用
AU774343B2 (en) * 1999-05-17 2004-06-24 Giampiero Valletta Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation
US7026319B1 (en) 1999-05-17 2006-04-11 Giampiero Valletta Use of vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation
US7291625B2 (en) 1999-05-17 2007-11-06 Giampero Valletta Use of a vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation

Also Published As

Publication number Publication date
CN1080855A (zh) 1994-01-19

Similar Documents

Publication Publication Date Title
JP2008542300A (ja) 炎症と関連した状態を予防及び治療するための組成物及び方法
EP3666267B1 (fr) Produit de combinaison contenant un composé limonide et de la metformine
KR102204299B1 (ko) 담팔수 추출물을 유효성분으로 포함하는 코로나 바이러스 치료제
KR101484587B1 (ko) 미역귀와 멍게껍질의 혼합물 추출액을 포함하는 아토피성 피부염 개선용 조성물
EP4014998B1 (fr) Produit de combinaison comprenant un limonoïde et des inhibiteurs de dpp-4
EP4014999B1 (fr) Produit de combinaison contenant un composé de limonine et un médicament à base de sulfonylurée
EP4014979B1 (fr) Produit de combinaison comprenant des limonoïdes et des inhibiteurs de sglt-2
CN1883484B (zh) 葫芦素药理用途
WO1994027624A1 (fr) Formulations de prevention du cancer contenant des vitamines et des mineraux
WO2020221184A1 (fr) Composition pharmaceutique ayant pour effet de réduire l'acide urique
CN103181561B (zh) 一种具有秋季养生保健作用的保健食品及其制备方法
AU9780598A (en) Serotonin containing formulation for oral administration and method of use
CN101062041B (zh) 葫芦素新的医药用途
CN101912109B (zh) 一种具有耐缺氧功能的保健食品及其制备方法
JP4371431B2 (ja) 抗アレルギー性組成物
JP4034146B2 (ja) 薬剤の副作用抑制剤
CN106349318B (zh) 一种五环三萜化合物在制备治疗肥胖症药物中的应用
CN109331093B (zh) 一种植物组合物及其应用
EP4157326A1 (fr) Combinaison de principes actifs, compositions les contenant et leur utilisation pour soutenir et renforcer le système immunitaire
CN109394977B (zh) 一种具有降血脂功能的中药组合物及其制备方法及应用
CN102362936A (zh) 鸡爪芋提取物的用途及其药品和保健品固体制剂、饮料制剂
CN109700819B (zh) 一种减肥降脂的药物组合物及其制备方法与用途
CN101209317B (zh) 一种具有解酒保肝作用的药物组合物
CN102743504B (zh) 一种减肥降脂的中药组合物、制剂及食品
JP2002371001A (ja) 白内障の予防または治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BR FI JP KR PL SE US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载